RIBECCA ribociclib a CDK46 inhibitor in ER breast cancer

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=XT_l4r85qfk

Wolfgang Janni, MD, PhD, Ulm University, Ulm, Germany, discusses the RIBECCA trial, a Phase III study evaluating ribociclib, a CDK4/6 inhibitor, in combinati...

Speaker: Wolfgang Janni, Institution: Ulm University, Event: VJVirtual, Event: SABCS 2020, Format: Interview, Subject: Breast Cancer, Field: Treatment, Field: Trial Updates, Trial: RIBECCA, NCT03096847, Medicines: Ribociclib, Medicines: Letrozole, ER+, metastatic
#############################